Navigation Links
China Sky One Medical, Inc. Appoints New Independent Director

HARBIN, China, Aug. 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced the appointment of Mr. William Wei Lee as an independent member of the Company's Board of Directors ("the Board") effective August 4, 2009. Mr. Jiang Qi-Feng resigned from the Board effective August 4, 2009. Following this appointment, China Sky One Medical's Board of Directors has seven members, four of whom are independent. Mr. Wei Lee also replaces Mr. Jiang as a member of the Audit Committee, Compensation Committee and Finance Committee of the Board of Directors, and as "audit committee financial expert" as defined by the SEC rules adopted pursuant to the Sarbanes-Oxley Act of 2002.

Mr. Wei Lee has over 15 years of experience in financial services and government relations, including investments, joint ventures, mergers & acquisitions and management consulting. From 2000 to 2002 he was a Senior Associate at McKinsey Management Consulting Co. Ltd. and in 2003 he was a Project Manager at Roland Berger Strategy Consultants Ltd. From 2004 to 2006, he served as Director of Strategic Development at TNT N.V., an Amsterdam-based provider of postal and logistics services, where he was responsible for M&A and China business strategy. Since 2007, Mr. Wei Lee has been a Managing Director with Transworld Capital Group, a U.S. investment service firm specializing in cross-border M&A and fund raising between U.S. and China. In 2008, he served as Chief Operating Officer (on loan) for Legend Media Corporation, a U.S.-listed company specializing in radio advertising in China. Mr. Wei Lee earned a Master's degree in Political Science from North Illinois University in 1989 and a Ph.D. in Political Science from Massachusetts Institute of Technology in 1994, where he completed MBA course work at Sloan School. He completed post-doctoral studies at the Fairbank Center for East Asia Studies, Harvard University, in 1995.

"We are very pleased to welcome Mr. Wei Lee to our Board of Directors, the majority of which is independent," said Mr. Yan-qing Liu, Chairman and CEO of China Sky One Medical. "We believe that his expertise in corporate governance at public companies in China and his experience in investments and management consulting will play a vital role in our development as a leading manufacturer of pharmaceuticals in China. We look forward to working with him as we continue to strengthen our corporate governance. We would also like to thank Mr. Jiang for his contributions to the Board over the last two years and wish him well in his career."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the change of independent directors. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-451-5399-4069

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915

SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations
2. American Oriental Bioengineering Honorably Elected a Top 20 Most Competitive Public Pharmaceutical Company in China
3. Sundia in Top 100 Fast-growth Outsourcing Companies in China
4. China Biologic Products Hosts its First Forum for Strategy and Development
5. NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China
6. China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results
7. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
8. China Clean Energy Provides Business Update
9. China Kangtai Cactus Biotech Retains Hawk Associates for Investor Relations Services
10. RainEarth (RNER) Continues to Expand its Marketing Force in China
11. Sinovac Receives Chinas First Influenza A (H1N1) Vaccine Order
Post Your Comments:
(Date:12/1/2015)... 2015 ) ... U.K. Virology and Bacteriology Testing Market: Sales ... Supplier Shares by Test, Innovative Technologies, Competitive ... --> ) has announced ... and Bacteriology Testing Market: Sales and Volume ...
(Date:11/30/2015)... , Dec. 1, 2015  An interventional radiology technique ... to the preliminary results of a study being presented today ... North America (RSNA). ... done for decades by interventional radiologists as a way to ... the procedure as a means of treating obesity is new. ...
(Date:11/30/2015)... /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today ... to its Board of Directors to replace Dr. ... wealth of experience as co-founder of Resverlogix, with expertise in ... --> --> Dr. Wong remarked, "I am ... Zenith,s long standing expertise in epigenetics and the advanced stage ...
(Date:11/30/2015)... JACKSONVILLE, Florida , November 30, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, today announced it will be presenting ... Event on December 1, 2015 at 2.30 PM PT. ... member and Strategic Advisor will be giving the presentation ...
Breaking Biology Technology:
(Date:11/18/2015)... York , November 18, 2015 ... Research has published a new market report titled  Gesture ... Trends, and Forecast, 2015 - 2021. According to the report, ... 2014 and is anticipated to reach US$29.1 bn by ... 2021. North America dominated ...
(Date:11/17/2015)... Paris , qui ... Paris , qui s,est tenu du ... leader de l,innovation biométrique, a inventé le premier scanner ... sur la même surface de balayage. Jusqu,ici, deux scanners ... les empreintes digitales. Désormais, un seul scanner est en ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
Breaking Biology News(10 mins):